Graphene oxide nanocells for impairing topoisomerase and DNA in cancer cells

Nandi, Aditi; Ghosh, Chandramouli; Bajpai, Aman; Basu, Sudipta

doi:10.1039/c9tb00336c

Cited by 7 publications

(4 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[195] Topotecan-topisomerase I inhibitor GO/TT/CisP/cholesterol-DOX encapsulated in a DSPE-PEG nanocell in vitro: HeLa cells 29% DLC and 40% DRE for TT, with pH-triggered drug release This nanocarrier has fluorescence imaging capabilities and displays remarkably higher anticancer efficacy compared to the free-drug combination due to the synchronised targeting of multiple targets in cancer cells at once. [196] PEI-GO-TT-CisP in vitro: HeLa cells 51% DLC for TT, no quantitative drug release data…”

Section: In Vitro: Mcf-7 Cellsmentioning

confidence: 99%

See 1 more Smart Citation

Carbon Nanomaterials (CNMs) in Cancer Therapy: A Database of CNM-Based Nanocarrier Systems

2023

View full text Add to dashboard Cite

Carbon nanomaterials (CNMs) are an incredibly versatile class of materials that can be used as scaffolds to construct anticancer nanocarrier systems. The ease of chemical functionalisation, biocompatibility, and intrinsic therapeutic capabilities of many of these nanoparticles can be leveraged to design effective anticancer systems. This article is the first comprehensive review of CNM-based nanocarrier systems that incorporate approved chemotherapy drugs, and many different types of CNMs and chemotherapy agents are discussed. Almost 200 examples of these nanocarrier systems have been analysed and compiled into a database. The entries are organised by anticancer drug type, and the composition, drug loading/release metrics, and experimental results from these systems have been compiled. Our analysis reveals graphene, and particularly graphene oxide (GO), as the most frequently employed CNM, with carbon nanotubes and carbon dots following in popularity. Moreover, the database encompasses various chemotherapeutic agents, with antimicrotubule agents being the most common payload due to their compatibility with CNM surfaces. The benefits of the identified systems are discussed, and the factors affecting their efficacy are detailed.

show abstract

Section: In Vitro: Mcf-7 Cellsmentioning

confidence: 99%

“…[198] This nanocarrier has fluorescence imaging capabilities and displays remarkably higher anticancer efficacy compared to the free-drug combination due to the synchronised targeting of multiple targets in cancer cells at once. [196] PEI-GO-TT-CisP in vitro: HeLa cells 51% DLC for TT, no quantitative drug release data…”

Section: In Vitro: Mcf-7 Cellsmentioning

confidence: 99%

Carbon Nanomaterials (CNMs) in Cancer Therapy: A Database of CNM-Based Nanocarrier Systems

2023

View full text Add to dashboard Cite

show abstract

“…V 2 CT z -ox 24 /V 2 CT z -ox 48 brought cell cycle effects, such as induction of abnormal proliferation potential in A375 cells. Effects on the cell cycle have been described in treatments with 2D materials [50,51] but such effects are not reported on the influence of MXenes. The ROS formation was dependent on the applied dose of the MXenes, in both cell lines.…”

Section: Xmenesmentioning

confidence: 99%

Vanadium and Melanoma: A Systematic Review

Amante

Sousa‐Coelho

Aureliano

2021

Metals

View full text Add to dashboard Cite

The application of metals in biological systems has been a rapidly growing branch of science. Vanadium has been investigated and reported as an anticancer agent. Melanoma is the most aggressive type of skin cancer, the incidence of which has been increasing annually worldwide. It is of paramount importance to identify novel pharmacological agents for melanoma treatment. Herein, a systematic review of publications including “Melanoma and Vanadium” was performed. Nine vanadium articles in several melanoma cells lines such as human A375, human CN-mel and murine B16F10, as well as in vivo studies, are described. Vanadium-based compounds with anticancer activity against melanoma include: (1) oxidovanadium(IV); (2) XMenes; (3) vanadium pentoxide, (4) oxidovanadium(IV) pyridinonate compounds; (5) vanadate; (6) polysaccharides vanadium(IV/V) complexes; (7) mixed-metal binuclear ruthenium(II)–vanadium(IV) complexes; (8) pyridoxal-based oxidovanadium(IV) complexes and (9) functionalized nanoparticles of yttrium vanadate doped with europium. Vanadium compounds and/or vanadium materials show potential anticancer activities that may be used as a useful approach to treat melanoma.

show abstract

“…[27][28][29][30][31] In this context, graphene oxide (GO) has garnered signicant interest owing to its biocompatibility and plethora of applications especially in cancer treatment for the delivery of therapeutics (drugs, genes, and proteins). [32][33][34][35][36][37][38][39][40][41][42] The superiority of GO stems from its unique 2dimensional structure combined with oxygen-rich functionalities (epoxide, carboxylic acids, and alcohols) present for tagging therapeutic entities. However, chemical conjugation of multiple drugs with hydrophilic functionalities in GO hugely compromises the solubility of the GO-drug conjugates for further biological applications.…”

Section: Introductionmentioning

confidence: 99%

Polymer conjugated graphene-oxide nanoparticles impair nuclear DNA and Topoisomerase I in cancer

2019

Self Cite

View full text Add to dashboard Cite

show abstract

Graphene oxide nanocells for impairing topoisomerase and DNA in cancer cells

Abstract: We have engineered graphene oxide based nanocell to target DNA topoisomerases and nuclear DNA in cancer cells to induce apoptosis.

Cited by 7 publications

References 49 publications

Carbon Nanomaterials (CNMs) in Cancer Therapy: A Database of CNM-Based Nanocarrier Systems

Carbon Nanomaterials (CNMs) in Cancer Therapy: A Database of CNM-Based Nanocarrier Systems

Vanadium and Melanoma: A Systematic Review

Polymer conjugated graphene-oxide nanoparticles impair nuclear DNA and Topoisomerase I in cancer

Contact Info

Product

Resources

About